Short answer
Cogent Biosciences, Inc. (COGT) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$96M
- −31.1% YoY · +1.0% QoQ
- EPS (diluted)
- −$0.52
- +1.9% YoY · +1.9% QoQ
Source: XBRL data from the Cogent Biosciences, Inc. (COGT) Q2 2026 10-Q on SEC EDGAR. USD.
Cogent Biosciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0; no product sales, unchanged from prior-year quarter
- Net loss $96.4M vs $73.5M YoY; operating loss $102.6M vs $75.6M
- Best R&D line bezuclastinib $25.6M; lowest early-stage programs $11.8M
- Cash, equivalents and marketable securities $792.3M; $71.4M post-quarter ATM proceeds
- Funding expected into late 2028; U.S. launch anticipated second half 2026 pending approval
Risk Factors
- No material risk-factor changes from December 31, 2025 Form 10-K
- Clinical-stage biotechnology risk remains significant, with additional unknown or immaterial risks potentially affecting results
- No newly triggered regulatory, legal, or compliance risk identified this quarter
- No specific liquidity, debt-maturity, currency, or concentration risk updated in the filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cogent Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.